Overview

A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

Status:
Completed
Trial end date:
2017-07-07
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America. The aim of the trial is to investigate Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects being overweight or with obesity
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S